BAT applies for PMTA from FDA for Vuse Pro device, promises to prevent minors from accessing e-cigarettes

BAT applies for PMTA from FDA for Vuse Pro device, promises to prevent minors from accessing e-cigarettes

On June 27, RJ Reynolds Vapor Company (RJRVC), a subsidiary of Reynolds American Inc, submitted the final pre-market tobacco product application (PMTA) for the Vuse Pro e-cigarette to the US FDA. The company said that Vuse Pro uses advanced age verification technology and mobile applications to ensure that only verified adults can use it.

On June 27, RJ Reynolds Vapor Company (RJRVC), an operating company of Reynolds American, a subsidiary of British American Tobacco (BAT), announced on its official website that it had submitted the final pre-market tobacco product application (PMTA) for its product Vuse Pro age-restricted device to the US Food and Drug Administration (FDA).

Vuse Pro is an electronic nicotine delivery system (ENDS) device platform that connects to a mobile application that verifies the consumer's age before use through a third-party provider to verify that the adult consumer is at least 21 years old and over the legal minimum purchase age for purchasing tobacco and atomizing products before unlocking. In addition, only verified adult users can unlock the device and use cartridges compatible with Vuse Pro.

The technology and mobile app also support features such as automatic locking and proximity locking to further ensure the safety of the device.

Tim Nestor, executive vice president of scientific research and development at Reynolds, said,

"Our submission of the PMTA application to the FDA reflects our commitment to providing choices for adult tobacco and consumers, while also preventing minors from accessing our products. We never want our products to fall into the hands of minors. The Vuse Pro ENDS platform provides a solution for adult consumers, limiting the use of minors while providing flavors and unique experiences that appeal to current adult smokers."

Under US law, any new tobacco product entering the market must be authorized by the FDA before it can be sold in the United States.

As part of the submission, Reynolds provided the FDA with nearly 80,000 pages of scientific data for review, including 97 scientific studies.